These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22359235)

  • 1. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.
    Baquero MT; Hanna JA; Neumeister V; Cheng H; Molinaro AM; Harris LN; Rimm DL
    Cancer; 2012 Oct; 118(19):4660-9. PubMed ID: 22359235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
    Baquero MT; Lostritto K; Gustavson MD; Bassi KA; Appia F; Camp RL; Molinaro AM; Harris LN; Rimm DL
    Breast Cancer Res; 2011 Nov; 13(5):R85. PubMed ID: 21888627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
    Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
    Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
    Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
    BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.
    Huang O; Jiang M; Zhang X; Xie Z; Chen X; Wu J; Liu H; Shen K
    Jpn J Clin Oncol; 2013 Nov; 43(11):1064-72. PubMed ID: 24031083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
    Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
    J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.
    Cao YW; Li WQ; Wan GX; Li YX; Du XM; Li YC; Li F
    J Exp Clin Cancer Res; 2014 Nov; 33(1):97. PubMed ID: 25420528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
    Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
    Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
    Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
    Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    Alford SH; Toy K; Merajver SD; Kleer CG
    Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
    Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.
    Nymoen DA; Slipicevic A; Holth A; Emilsen E; Hetland Falkenthal TE; Tropé CG; Reich R; Flørenes VA; Davidson B
    Hum Pathol; 2016 Aug; 54():74-81. PubMed ID: 27063471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
    Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of triple negative phenotype on breast cancer prognosis.
    Kaplan HG; Malmgren JA
    Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer.
    Zhang Y; Yao L; Zhang X; Ji H; Wang L; Sun S; Pang D
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1245-53. PubMed ID: 21691749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.